Patents Assigned to Aragon Pharmaceuticals, Inc.
-
Patent number: 10308630Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: May 9, 2018Date of Patent: June 4, 2019Assignees: Sloan-Kettering Institute for Cancer Research, Aragon Pharmaceuticals, Inc.Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
-
Patent number: 10052314Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.Type: GrantFiled: December 21, 2017Date of Patent: August 21, 2018Assignee: Aragon Pharmaceuticals, Inc.Inventor: Isan Chen
-
Patent number: 10023556Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.Type: GrantFiled: September 9, 2016Date of Patent: July 17, 2018Assignee: Aragon Pharmaceuticals, Inc.Inventors: Nicholas D. Smith, Celine Bonnefous, Jackaline D. Julien
-
Patent number: 9994545Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: September 12, 2016Date of Patent: June 12, 2018Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer ResearchInventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
-
Patent number: 9884054Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.Type: GrantFiled: September 23, 2013Date of Patent: February 6, 2018Assignee: ARAGON PHARMACEUTICALS, INC.Inventor: Isan Chen
-
Patent number: 9617602Abstract: Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of third-generation androgen receptor modulators. Also described herein are third-generation androgen receptor modulators that inhibit the activity of the modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions, including cancers, such as castration resistant prostate cancers, that are mediated or dependent upon androgen receptors.Type: GrantFiled: July 26, 2013Date of Patent: April 11, 2017Assignee: ARAGON PHARMACEUTICALS, INC.Inventors: James David Joseph, Jeffrey H Hager, John Lee Sensintaffar, Nhin Lu, Jing Qian, Nicholas D Smith
-
Patent number: 9481663Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: GrantFiled: June 4, 2013Date of Patent: November 1, 2016Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer ResearchInventors: Anna Dilhas, Mark R Herbert, Ouathek Ouerfelli, Nicholas D Smith
-
Patent number: 9481664Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.Type: GrantFiled: March 12, 2015Date of Patent: November 1, 2016Assignee: Aragon Pharmaceuticals, Inc.Inventors: Nicholas D. Smith, Celine Bonnefous, Jackaline D. Julien
-
Patent number: 9340524Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.Type: GrantFiled: January 9, 2014Date of Patent: May 17, 2016Assignee: Aragon Pharmaceuticals, Inc.Inventors: Isan Chen, Jeffrey H Hager, Edna Chow Maneval, Mark R Herbert, Nicholas D Smith
-
Patent number: 9108944Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.Type: GrantFiled: February 16, 2011Date of Patent: August 18, 2015Assignee: ARAGON PHARMACEUTICALS, INC.Inventors: Nicholas D. Smith, Celine Bonnefous, Jackaline D. Julien
-
Publication number: 20150133481Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.Type: ApplicationFiled: June 4, 2013Publication date: May 14, 2015Applicant: Aragon Pharmaceuticals, Inc.and Sloan -Kettering Institute for Cancer ResearchInventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nichola D. Smith
-
Publication number: 20140199236Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.Type: ApplicationFiled: January 9, 2014Publication date: July 17, 2014Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
-
Publication number: 20140088129Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.Type: ApplicationFiled: September 23, 2013Publication date: March 27, 2014Applicant: Aragon Pharmaceuticals, Inc.Inventor: Isan Chen
-
Publication number: 20130231333Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: September 15, 2011Publication date: September 5, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Mark R. Herbert, Celine Bonnefous, Karensa L. Douglas
-
Patent number: 8455534Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: September 13, 2012Date of Patent: June 4, 2013Assignee: Aragon Pharmaceuticals, Inc.Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Celine Bonnefous
-
Publication number: 20130137746Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 15, 2011Publication date: May 30, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Steven P. Govek, Nicholas D. Smith
-
Publication number: 20130116258Abstract: Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.Type: ApplicationFiled: February 16, 2011Publication date: May 9, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Nicholas D. Smith, Celine Bonnefous, Jackaline D. Julien
-
Publication number: 20130116232Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 8, 2011Publication date: May 9, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Nicholas D. Smith
-
Publication number: 20130012561Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Nicholas D. SMITH, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Celine Bonnefous
-
Patent number: 8299112Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: GrantFiled: September 15, 2011Date of Patent: October 30, 2012Assignee: Aragon Pharmaceuticals, Inc.Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Celine Bonnefous